Akebia Therapeutics, Inc. Recorded Big Gain
Tue, May 05, 2020 at 05:30 PM
Akebia Therapeutics, Inc. (AKBA:NASDAQ) rocketted at $11.95, a gain of 38%. On Mon 04 May 20, AKBA:NASDAQ hit a New 2-Week High of $8.66. The stock appeared on our News Catalysts scanner on Tue 28 Apr 20 at 05:25 PM in the 'EARNINGS' category. From Mon 20 Apr 20, the stock recorded 60.00% Up Days and 72.73% Green Days
The share price of the company has been moving sideways in recent weeks.
About Akebia Therapeutics, Inc. (AKBA:NASDAQ)
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
Top 10 Gainers:
- Portola Pharmaceuticals, Inc. (PTLA:NASDAQ), 130.03%
- Ritter Pharmaceuticals, Inc. (RTTR:NASDAQ), 87.68%
- Genprex, Inc. (GNPX:NASDAQ), 51.52%
- DropCar, Inc. (DCAR:NASDAQ), 49.08%
- BioPharmX Corporation (BPMX:NYSEMKT), 39.43%
- Staffing 360 Solutions, Inc. (STAF:NASDAQ), 38.89%
- Adverum Biotechnologies, Inc. (ADVM:NASDAQ), 38.35%
- Conatus Pharmaceuticals Inc. (CNAT:NASDAQ), 38.27%
- Akebia Therapeutics, Inc. (AKBA:NASDAQ), 37.99%
- Lightbridge Corporation (LTBR:NASDAQ), 37.78%